“The FDA considers both unwanted harmful effects and lack of efficacy to be adverse events. When considering candidates for pharmacogenomic relabeling, the FDA evaluates the severity of the adverse reaction, the degree to which genetics predicts the reaction, and the total number of individuals likely to be affected. These factors are important in assessing the […]
One-on-One w/MedStar Health’s Gerry Higgins – Part 2
Gerald Higgins, PhD., MBA, MS, is not your typical CIO — that’s because Higgins is a chief innovation officer. Getting paid not to carry out EMR implementations or persuade physicians to embrace CPOE, Higgins is remunerated to “see what’s happening one or two hills over the horizon.” With a dizzying array of jobs and accomplishments […]
One-on-One w/MedStar Health’s Gerry Higgins
Gerald Higgins, PhD., MBA, MS, is not your typical CIO — that’s because Higgins is a chief innovation officer. Getting paid not to carry out EMR implementations or persuade physicians to embrace CPOE, Higgins is remunerated to “see what’s happening one or two hills over the horizon.” With a dizzying array of jobs and accomplishments […]